Nisa Investment Advisors LLC Reduces Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Nisa Investment Advisors LLC lessened its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 97.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,607 shares of the biotechnology company’s stock after selling 199,828 shares during the quarter. Nisa Investment Advisors LLC’s holdings in ADMA Biologics were worth $52,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of ADMA. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of ADMA Biologics during the 1st quarter valued at about $17,221,000. Rice Hall James & Associates LLC bought a new stake in ADMA Biologics during the first quarter valued at approximately $7,963,000. Castleark Management LLC purchased a new stake in ADMA Biologics during the first quarter valued at approximately $5,400,000. Hillsdale Investment Management Inc. raised its position in ADMA Biologics by 41,893.3% in the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock worth $4,157,000 after acquiring an additional 628,400 shares during the period. Finally, Russell Investments Group Ltd. boosted its stake in shares of ADMA Biologics by 90.7% during the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after acquiring an additional 556,175 shares during the last quarter. Institutional investors own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 100,000 shares of the business’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $10.72, for a total value of $1,072,000.00. Following the sale, the chief executive officer now owns 2,081,475 shares in the company, valued at approximately $22,313,412. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock opened at $18.40 on Monday. The company has a market capitalization of $4.27 billion, a price-to-earnings ratio of -920.00 and a beta of 0.55. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91. The stock’s 50-day simple moving average is $13.20 and its 200-day simple moving average is $9.26. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $18.42.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The company had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. During the same period in the previous year, the firm earned ($0.02) EPS. The firm’s revenue was up 78.4% compared to the same quarter last year. As a group, analysts expect that ADMA Biologics, Inc. will post 0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. HC Wainwright upped their price objective on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Mizuho raised their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Cantor Fitzgerald boosted their price objective on ADMA Biologics from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Raymond James raised their target price on shares of ADMA Biologics from $8.00 to $10.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.